QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)

Nevro (NVRO) Price Target & Analyst Ratings

$27.29
-0.49 (-1.76%)
(As of 05/18/2023 ET)
Compare
Today's Range
$26.79
$27.63
50-Day Range
$26.68
$39.32
52-Week Range
$26.40
$53.34
Volume
467,758 shs
Average Volume
606,213 shs
Market Capitalization
$977.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.82

Nevro Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$46.09
68.89% Upside
High Prediction$95.00
Average Prediction$46.09
Low Prediction$31.00
TypeCurrent
5/18/22 to 5/18/23
1 Month Ago
4/18/22 to 4/18/23
3 Months Ago
2/17/22 to 2/17/23
1 Year Ago
5/18/21 to 5/18/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
4 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$46.09$47.80$55.00$92.82
Predicted Upside68.89% Upside24.65% Upside17.09% Upside7.46% Upside
Get Nevro Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.


NVRO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nevro Stock vs. The Competition

TypeNevroMedical CompaniesS&P 500
Consensus Rating Score
2.08
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside68.89% Upside1,414.32% Upside164.04% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/18/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$40.00 ➝ $32.00+15.19%
5/15/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$40.00+46.41%
4/27/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$37.00 ➝ $34.00-1.71%
4/13/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$40.00+9.65%
2/6/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$67.00 ➝ $72.00+80.95%
1/17/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$40.00+10.93%
1/11/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight$43.00 ➝ $37.00+3.93%
1/6/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$49.00 ➝ $46.00+17.17%
11/3/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$50.00 ➝ $40.00-2.91%
11/2/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Vazquez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform$31.00-16.98%
5/26/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform$125.00 ➝ $95.00+119.96%
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NVRO Price Target - Frequently Asked Questions

What is Nevro's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Nevro stock is Hold based on the current 2 sell ratings, 7 hold ratings and 3 buy ratings for NVRO. The average twelve-month price prediction for Nevro is $46.09 with a high price target of $95.00 and a low price target of $31.00. Learn more on NVRO's analyst rating history.

Do Wall Street analysts like Nevro more than its competitors?

Analysts like Nevro less than other Medical companies. The consensus rating for Nevro is Hold while the average consensus rating for medical companies is Buy. Learn more on how NVRO compares to other companies.

Is Nevro being upgraded by Wall Street analysts?

Over the previous 90 days, Nevro's stock had 1 upgrade by analysts.

Does Nevro's stock price have much upside?

According to analysts, Nevro's stock has a predicted upside of 25.28% based on their 12-month price targets.

What analysts cover Nevro?

Nevro has been rated by Mizuho, Oppenheimer, Piper Sandler, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:NVRO) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -